Glaxosmithkline Pharmaceuticals liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

15.67×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.13×	2.13×	1.89×	1.98×	2.04×
1.87×	1.87×	1.64×	1.63×	1.70×
2,493	2,493	1,657	877	553
2,006	2,006	1,701	1,487	1,382

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLAXO₹2,515.10

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersPFIZER ABBOTINDIA MEDANTA ANTHEM AJANTPHARM IPCALAB GLENMARK BIOCONMcap ₹42,608 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	15.67
Current Ratio	2.04	1.98	1.89	2.13	2.13
Quick Ratio	1.70	1.63	1.64	1.87	1.87
Cash, Equiv & ST Investments	553.2	877.4	1,657.1	2,493.0	2,493.0
Working Capital	1,381.9	1,487.1	1,700.7	2,005.6	2,005.6

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.